Loading clinical trials...
Loading clinical trials...
TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion
Conditions
Interventions
4 mg CLS-TA
Sham
+1 more
Locations
14
United States
Phoenix, Arizona, United States
Beverly Hills, California, United States
San Diego, California, United States
Boynton Beach, Florida, United States
Atlanta, Georgia, United States
Baltimore, Maryland, United States
Start Date
January 1, 2015
Primary Completion Date
March 1, 2016
Completion Date
March 1, 2016
Last Updated
February 8, 2021
NCT07449936
NCT07449923
NCT07228559
NCT05802329
NCT06781255
NCT05976139
Lead Sponsor
Clearside Biomedical, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions